NAFLD in the Elderly

Saleh A Alqahtani,1,2 Jörn M Schattenberg3 1Liver Transplantation Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia; 2Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, MD, USA; 3Metabolic Liver Research Program, I. Department of Medic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alqahtani SA, Schattenberg JM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	liver disease aging fatty liver nash senescence regeneration Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/420c52d3a35f445b914795659cbe8707
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:420c52d3a35f445b914795659cbe8707
record_format	dspace
spelling	oai:doaj.org-article:420c52d3a35f445b914795659cbe87072021-12-02T18:03:14ZNAFLD in the Elderly1178-1998https://doaj.org/article/420c52d3a35f445b914795659cbe87072021-09-01T00:00:00Zhttps://www.dovepress.com/nafld-in-the-elderly-peer-reviewed-fulltext-article-CIAhttps://doaj.org/toc/1178-1998Saleh A Alqahtani,1,2 Jörn M Schattenberg3 1Liver Transplantation Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia; 2Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, MD, USA; 3Metabolic Liver Research Program, I. Department of Medicine, University Medical Center, Mainz, GermanyCorrespondence: Jörn M SchattenbergMetabolic Liver Research Program, I. Department of Medicine, University Medical Center of the Johannes Gutenberg-University, Langenbeckstrasse 1, Mainz, 55131, GermanyEmail joern.schattenberg@unimedizin-mainz.deAbstract: Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent disease globally. Current estimates are that 24% of the adult population, thus, one billion individuals worldwide, are affected. Interestingly, the prevalence of fatty liver seems to peak between 40&boxh;50 years of age in males and 60&boxh;69 years in females, often slightly decreasing in older (> 70 years) cohorts. Furthermore, several risk factors for NAFLD development, such as hypertension, diabetes, hyperlipidemia, and obesity are higher in older adults. The diagnosis and management strategies in older adults are sometimes challenging, and certain age-specific factors have to be taken into account by healthcare professionals. In this review, we provide an overview of considerations relevant to the management and diagnosis of NAFLD in older adults (age > 65 years) and discuss the types of pharmacological interventions available for the management of non-alcoholic steatohepatitis (NASH) in the aging population.Keywords: liver disease, aging, fatty liver, NASH, senescence, regenerationAlqahtani SASchattenberg JMDove Medical Pressarticleliver diseaseagingfatty livernashsenescenceregenerationGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 16, Pp 1633-1649 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	liver disease aging fatty liver nash senescence regeneration Geriatrics RC952-954.6
spellingShingle	liver disease aging fatty liver nash senescence regeneration Geriatrics RC952-954.6 Alqahtani SA Schattenberg JM NAFLD in the Elderly
description	Saleh A Alqahtani,1,2 Jörn M Schattenberg3 1Liver Transplantation Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia; 2Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, MD, USA; 3Metabolic Liver Research Program, I. Department of Medicine, University Medical Center, Mainz, GermanyCorrespondence: Jörn M SchattenbergMetabolic Liver Research Program, I. Department of Medicine, University Medical Center of the Johannes Gutenberg-University, Langenbeckstrasse 1, Mainz, 55131, GermanyEmail joern.schattenberg@unimedizin-mainz.deAbstract: Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent disease globally. Current estimates are that 24% of the adult population, thus, one billion individuals worldwide, are affected. Interestingly, the prevalence of fatty liver seems to peak between 40&boxh;50 years of age in males and 60&boxh;69 years in females, often slightly decreasing in older (> 70 years) cohorts. Furthermore, several risk factors for NAFLD development, such as hypertension, diabetes, hyperlipidemia, and obesity are higher in older adults. The diagnosis and management strategies in older adults are sometimes challenging, and certain age-specific factors have to be taken into account by healthcare professionals. In this review, we provide an overview of considerations relevant to the management and diagnosis of NAFLD in older adults (age > 65 years) and discuss the types of pharmacological interventions available for the management of non-alcoholic steatohepatitis (NASH) in the aging population.Keywords: liver disease, aging, fatty liver, NASH, senescence, regeneration
format	article
author	Alqahtani SA Schattenberg JM
author_facet	Alqahtani SA Schattenberg JM
author_sort	Alqahtani SA
title	NAFLD in the Elderly
title_short	NAFLD in the Elderly
title_full	NAFLD in the Elderly
title_fullStr	NAFLD in the Elderly
title_full_unstemmed	NAFLD in the Elderly
title_sort	nafld in the elderly
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/420c52d3a35f445b914795659cbe8707
work_keys_str_mv	AT alqahtanisa nafldintheelderly AT schattenbergjm nafldintheelderly
_version_	1718378802205163520

NAFLD in the Elderly

Ejemplares similares